Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.
Enrico D, Lacroix L, Chen J, Rouleau E, Scoazec JY, Loriot Y, Tselikas L, Jovelet C, Planchard D, Gazzah A, Mezquita L, Ngo-Camus M, Michiels S, Massard C, Recondo G, Facchinetti F, Remon J, Soria JC, André F, Vassal G, Friboulet L, Besse B.
Enrico D, et al. Among authors: planchard d.
JTO Clin Res Rep. 2020 Mar 7;1(2):100023. doi: 10.1016/j.jtocrr.2020.100023. eCollection 2020 Jun.
JTO Clin Res Rep. 2020.
PMID: 34589930
Free PMC article.